NEW YORK, July 29, 2026 -(BUSINESS WIRE)- VB Spine LLC (“VB Spine”) today announced that the U.S. Food and Drug Administration (FDA) granted two 510(k) clearances that expand the indications for its Vitoss® Bone Graft Substitute and interbody cage portfolio. Vitoss is a registered trademark of Stryker Corporation or one of its affiliates and is used by VB Spine under license. VB Spine disclaims any obligation to update forward-looking statements except as required by law. Focused on people, partnerships and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. For more information on VB Spine, please visit www.vbspineco.com.